Global Q1-Q3 2013 Pharma, Medical, and Biotech M&A Trend Report
07 November, 2013
Mergermarket releases its Global Q1-Q3 2013 Pharma, Medical, and Biotech M&A Trend Report
• Global M&A activity in the Pharma, Medical & Biotech (PMB) has increased 26.1% compared to the same period in 2012 (up until end of October) with US$ 141bn-worth of deals compared to US$ 111.8bn this time last year.
• After a drop in M&A value in Q1 to US$ 13.9bn from Q4 2012’s three and a half year high (US$ 80.8bn), the quarterly value has been sporadic throughout 2013. Q3’s US$ 49.1bn-worth of deals was down 24% from Q2 (US$ 64.6bn) but compared to Q3 2012’s US$ 27bn, it showed a sharp 81.9% increase.
• The PMB sector has fluctuated in value every year since 2007 (US$ 219.8bn). Last year’s US$ 180.5bn-worth of deals marked the third time to see an annual decrease since 2007, down 10.4% from 2011 (US$ 201.5bn) even though the number of deals has increased every year since 2009 which has led to 2012 ending with 1,030 deals.
Please see here for the full report.